Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Integrating Minimally Invasive Biomarkers of Estrogen Signaling to Detect Endocrine Therapy Resistance in Metastatic Invasive Lobular Breast Cancer

NCT06067503 is registered in ClinicalTrials.gov with University of Wisconsin, Madison as lead sponsor.

NCT NCT06067503
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06067503 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Integrating Minimally Invasive Biomarkers of Estrogen Signaling to Detect Endocrine Therapy Resistance in Metastatic Invasive Lobular Breast Cancer
Lead sponsor
University of Wisconsin, Madison
Phase
Phase 2
Overall status
Recruiting
Start date
April 30, 2024
Completion date
December 31, 2026
Enrollment
8 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, lobular breast carcinoma, metastatic cancer